Physician profile
Weldon W Haw
NPI 1710945357
$21,441.25
in general payments reported to CMS, 2019-2025
19 companies · $3,468 in 2025
The $3,468 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,704 · 2020: $45.44 · 2021: $1,177 · 2022: $610 · 2023: $2,277 · 2024: $5,160 · 2025: $3,468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,431 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,790 · Food and Beverage: $1,609 · Honoraria: $58.00 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,430.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,790.00 |
| Food and Beverage | $1,608.68 |
| Honoraria | $58.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $6,320.96 | 2019 | |
| Alcon Vision LLC | $5,745.11 | 2019-2025 | Hydrus Microstent, Clareon, Unity |
| Glaukos Corporation | $2,610.98 | 2023-2025 | Idose, Istent Inject Trabecular Micro-Bypass System, Radius |
| Vertex Pharmaceuticals Incorporated | $2,016.66 | 2021-2025 | |
| Dr.Reddy'S Laboratories,INC. | $961.00 | 2023-2024 | |
| Cipla USA INC. | $706.00 | 2025 | |
| Becton, Dickinson and Company | $595.33 | 2025 | |
| Alexion Pharmaceuticals, INC. | $575.00 | 2021 | |
| Sentynl Therapeutics, INC. | $569.00 | 2022 | |
| Tersera Therapeutics LLC | $513.00 | 2025 | Margenza |
| Tarsus Pharmaceuticals, INC. | $392.88 | 2025 | Xdemvy |
| C. R. Bard, INC. & Subsidiaries | $90.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $87.64 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $79.41 | 2023-2025 | Envista Envy Iol, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $70.29 | 2022-2025 | Tecnis Simplicity, Tecnis Iol |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $55.53 | 2021 | |
| Shire North American Group INC | $26.29 | 2019 | |
| Mallinckrodt Hospital Products INC. | $14.67 | 2025 | Acthar |
| Biotissue Holdings INC. | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weldon Haw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.